#Taiwan #Taipei #Angel Lee #PhytoHealth #PG2®

Angel Lee: A Pioneer in Cancer-Related Fatigue Treatment

Angel Lee, the CEO of PhytoHealth Corporation, has been honored as one of Taiwan's 27th Ten Outstanding Young Women for her significant contributions in the healthcare sector. Particularly, her focus on developing PG2® Lyo. Injection, the world’s first prescription medication designed specifically for moderate to severe cancer-related fatigue (CRF), has garnered her national recognition. This accolade not only highlights her achievements but also the crucial role that PhytoHealth plays in addressing a pressing issue in cancer treatment.

The Development of PG2®

PG2® is a groundbreaking pharmaceutical solution derived from refined polysaccharides of Astragalus membranaceus, a medicinal plant noted in the WHO’s Selected Medicinal Plants monographs. This new botanical drug, which has received approval in Taiwan, is regarded as the first of its kind and effectively treats cancer-related fatigue across multiple medical institutions in the country. The drug is even covered by Taiwan's National Health Insurance for eligible breast cancer patients, marking a significant step forward in patient care.

Historically, cancer-related fatigue has been a debilitating condition that differs from regular tiredness. It impacts patients throughout their treatment regimen but has been largely overlooked in clinical settings. Angel Lee and her team at PhytoHealth have worked diligently to shift the perception of CRF from an often-ignored aspect of cancer care to a recognized and treatable condition. Their collaborative efforts with the medical community in Taiwan have led to the establishment of the first clinical guidelines for CRF, emphasizing the importance of this issue.

Advancements in Cancer Support Care

Under Lee’s leadership, PhytoHealth is not just focused on PG2®. The company is committed to generating clinical evidence surrounding their proprietary platform known as refined Astragalus polysaccharides (rAPS®) and is actively investigating its broader applications in oncology support care. As part of their mission, PhytoHealth seeks partnerships with international pharmaceutical and healthcare entities to expand the global reach of PG2® and advance innovative botanical drug therapies.

“We view this recognition not just as a personal honor, but as a significant responsibility,” said Lee. “Our aim is to translate scientific research into real benefits for patients. We will continue collaborating with medical and industrial partners worldwide, enhancing cancer support care and promoting Taiwan’s biotech innovations on a global scale.”

Angel Lee’s Background

Angel Lee holds a degree in accounting from National Taiwan University and an MBA from Carnegie Mellon University. Before her prominent roles in biotechnology, she gained valuable experience at Deloitte and Johnson & Johnson’s Janssen division, equipping her with the skills necessary to make impactful decisions in a complex industry.

About PhytoHealth Corporation

Based in Taiwan, PhytoHealth Corporation is a biotechnology enterprise dedicated to the research, development, and commercialization of innovative therapies, with a distinct focus on botanical drug development. Their portfolio includes PG2® for cancer-related fatigue and Oraphine®, an oral analgesic aimed at treating moderate to severe pain. Leveraging its refined polysaccharide platform (rAPS®), PhytoHealth continues to push forward with clinical research while seeking international collaborations to introduce Taiwan's health innovations to global markets.

Conclusion

Angel Lee's leadership at PhytoHealth Corporation marks a new era in cancer treatment research. Through her efforts, she is not only enhancing the lives of cancer patients but also setting a benchmark for how medical conditions like cancer-related fatigue should be addressed. As the journey continues, Lee and her team aim to bring further innovations that will undoubtedly impact the landscape of cancer care.